Last reviewed · How we verify
Dmae 1549 (DMAE)
At a glance
| Generic name | DMAE |
|---|---|
| Sponsor | Professional Complementary Health Formulas |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
- bloating
- headache
- insomnia
- irritability
Common side effects
Key clinical trials
- Effectiveness of a Bilayering Serum and Cream Containing GABA, DMAE, Cysteamine, and Bakuchiol for Skin Whitening and Anti-Aging (PHASE2)
- DMAE Oleate for Facial Skin Firmness and Fine Lines in Healthy Adults (NA)
- Safety and Tolerability of Pharmaton Capsules in Healthy Volunteers (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dmae 1549 CI brief — competitive landscape report
- Dmae 1549 updates RSS · CI watch RSS
- Professional Complementary Health Formulas portfolio CI